Business Context and Reporting Period
This Form 6-K filing by GSK plc, dated March 5, 2024, serves as a notification of the submission of the company's 2023 Annual Report on Form 20-F. The filing covers the audited financial statements for the fiscal year ended December 31, 2023. GSK is described as a global biopharma company focused on uniting science, technology, and talent to address disease.
Key Financial Metrics
The provided text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. This filing acts solely as a cover document announcing the availability of the full Annual Report on Form 20-F, which contains the detailed audited financial data.
Material Changes
The filing text does not provide specific data regarding material changes in financial performance compared to prior periods. Investors are directed to the full 2023 Annual Report on Form 20-F for comparative analysis.
Guidance, Outlook, and Risks
The filing includes a cautionary statement regarding forward-looking statements, noting that projections are subject to risks and uncertainties that may cause actual results to differ materially. Specific risk factors are referenced as being detailed under Item 3.D "Risk factors" in the 2023 Annual Report on Form 20-F. No specific guidance or management commentary on future performance is included in this text.
Important Facts for Investors to Verify
- Access the full 2023 Annual Report on Form 20-F at www.gsk.com/corporatereporting or www.sec.gov for audited financial figures.
- Review Item 3.D "Risk factors" in the Annual Report for detailed risk disclosures.
- Note that hard copies of the Annual Report and the Notice of Annual General Meeting will be available on or about March 25, 2024.
- Shareholders may request free hard copies of audited financial statements via Equiniti Limited (UK), J.P. Morgan Chase Bank (US), or the GSK Response Center (US).